Prognostic value of an integrated immune-inflammatory phenotype in surgically treated cervical cancer: survival modeling and immunohistochemical validation - Scorecard - MDSpire
Advertisement
Prognostic value of an integrated immune-inflammatory phenotype in surgically treated cervical cancer: survival modeling and immunohistochemical validation
Clinical Scorecard: Evaluating the Prognostic Significance of a Combined Immune-Inflammatory Profile in Cervical Cancer Patients Post-Surgery: Survival Analysis and Immunohistochemical Assessment
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Patients with cervical cancer who underwent primary surgery, specifically those with FIGO IIIC disease.
Care Setting
Key Highlights
C-index
Guideline-Based Recommendations
Diagnosis
Management
Consider specific postoperative treatments based on integrated immune-inflammatory phenotype.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with cervical cancer post-surgery
Integrated immune-inflammatory phenotype may guide postoperative management.
The clinical-stage cancer biotech raised $670 million in an upsized Nasdaq debut, with a further $75 million expected from a concurrent Regeneron private placement
